Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure

December 8, 2018 updated by: Sherief Abd-Elsalam

Clinical and Economical Study Evaluating the Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure

Clinical and Economic study of some new biomarkers in chronic heart failure.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study aimed at evaluation of the clinical and economic value of some new biomarkers in chronic heart failure.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Elgharbia
      • Tanta, Elgharbia, Egypt, 35111
        • Recruiting
        • Sherief Abd-Elsalam
        • Contact:
          • Nermin W Ishak, Msc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • NYHA-Class II-IV

Exclusion Criteria:

  • Liver or renal dysfunction. --DM

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: DIAGNOSTIC
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: New york Heart Association Class II-IV
New york Heart Association Class II-IV heart failure
Diagnostic test: New york Heart Association Class II-IV
New york Heart Association Class II-IV " study of markers"
Other Names:
  • Severe heart failure
ACTIVE_COMPARATOR: New york Heart Association Class I
New york Heart Association Class I with no heart failure
Diagnostic test: New york Heart Association Class I
New york Heart Association Class I
Other Names:
  • No heart failure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with elevated markers (IL17)
Time Frame: 6 months
Number of participants with elevated markers (IL17)
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sherief Abd-Elsalam

Investigators

  • Principal Investigator: Osama M Ibrahim, Prof, Prof of Clinical Pharmacy
  • Study Director: Medhat M Eshmawy, Prof, Cardiology Department- Tanta University
  • Study Chair: Nermin W Ishaq, Msc, Clinical pharmacy Department- Tanta University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 1, 2018

Primary Completion (ANTICIPATED)

October 1, 2026

Study Completion (ANTICIPATED)

October 1, 2027

Study Registration Dates

First Submitted

December 7, 2018

First Submitted That Met QC Criteria

December 8, 2018

First Posted (ACTUAL)

December 11, 2018

Study Record Updates

Last Update Posted (ACTUAL)

December 11, 2018

Last Update Submitted That Met QC Criteria

December 8, 2018

Last Verified

December 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Heart failure

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe